Equities Analysts Issue Forecasts for ACTU FY2030 Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Actuate Therapeutics in a note issued to investors on Monday, April 13th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of $2.43 per share for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock.

Actuate Therapeutics (NASDAQ:ACTU) last issued its earnings results on Thursday, March 26th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06.

ACTU has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Friday, March 27th. Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Actuate Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

Actuate Therapeutics Stock Performance

Shares of NASDAQ:ACTU opened at $2.09 on Tuesday. Actuate Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $11.99. The business has a 50-day simple moving average of $3.11 and a two-hundred day simple moving average of $5.33. The firm has a market cap of $49.55 million, a price-to-earnings ratio of -1.99 and a beta of 0.85.

Institutional Investors Weigh In On Actuate Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ACTU. Voss Capital LP increased its position in shares of Actuate Therapeutics by 213.2% during the 3rd quarter. Voss Capital LP now owns 896,278 shares of the company’s stock valued at $5,996,000 after purchasing an additional 610,138 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Actuate Therapeutics during the 4th quarter valued at about $579,000. BIOS Capital Management LP increased its position in shares of Actuate Therapeutics by 0.9% during the 3rd quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock valued at $67,234,000 after purchasing an additional 84,917 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Actuate Therapeutics by 252.5% during the 2nd quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after purchasing an additional 84,561 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Actuate Therapeutics by 19.5% during the 3rd quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock valued at $2,114,000 after purchasing an additional 51,546 shares during the last quarter.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.